Ironwood Pharmaceuticals, Inc. (IRWD)
Largest Insider Buys in Sector
IRWD Stock Price History Chart
IRWD Stock Performance
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain …
Insider Activity of Ironwood Pharmaceuticals, Inc.
Over the last 12 months, insiders at Ironwood Pharmaceuticals, Inc. have bought $160,420 and sold $5.86M worth of Ironwood Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ironwood Pharmaceuticals, Inc. have bought $7.81M and sold $4.72M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Emany Sravan Kumar (SVP, Chief Financial Officer) — $100,216. Duane Jon R (director) — $60,204.
The last purchase of 6,920 shares for transaction amount of $60,204 was made by Duane Jon R (director) on 2024‑03‑06.
List of Insider Buy and Sell Transactions, Ironwood Pharmaceuticals, Inc.
| 2024-11-18 | Sale | SVP, COO and CFO | 11,001 0.007% | $4.08 | $44,884 | -12.87% | ||
| 2024-11-18 | Sale | SVP, Chief Business Officer | 5,360 0.0034% | $4.08 | $21,869 | -12.87% | ||
| 2024-08-12 | Sale | Chief Legal Officer | 9,910 0.0063% | $4.27 | $42,316 | +0.24% | ||
| 2024-08-12 | Sale | Principal Accounting Officer | 3,107 0.002% | $4.27 | $13,267 | +0.24% | ||
| 2024-06-10 | Sale | director | 22,766 0.0138% | $6.29 | $143,198 | -32.03% | ||
| 2024-06-07 | Sale | director | 35,574 0.0233% | $6.61 | $235,144 | -29.92% | ||
| 2024-06-06 | Sale | director | 44,426 0.0276% | $6.36 | $282,549 | -30.85% | ||
| 2024-05-20 | Sale | Chief Executive Officer | 67,618 0.0427% | $6.45 | $436,136 | -29.52% | ||
| 2024-05-20 | Sale | CMO,SVP,Head-Res&Drug | 16,128 0.0102% | $6.45 | $104,026 | -29.52% | ||
| 2024-05-20 | Sale | Chief Legal Officer | 17,404 0.011% | $6.45 | $112,256 | -29.52% | ||
| 2024-05-20 | Sale | SVP, Chief Business Officer | 22,725 0.0144% | $6.45 | $146,576 | -29.52% | ||
| 2024-03-06 | director | 6,920 0.0045% | $8.70 | $60,204 | -30.45% | |||
| 2024-03-04 | SVP, Chief Financial Officer | 10,684 0.0069% | $9.38 | $100,216 | -35.41% | |||
| 2024-02-12 | Sale | Chief Executive Officer | 177,164 0.1118% | $15.24 | $2.7M | -59.73% | ||
| 2024-02-12 | Sale | CMO,SVP,Head-Res&Drug | 38,618 0.0244% | $15.24 | $588,538 | -59.73% | ||
| 2024-02-12 | Sale | Chief Legal Officer | 47,380 0.0299% | $15.24 | $722,071 | -59.73% | ||
| 2024-02-12 | Sale | SVP, Chief Business Officer | 9,846 0.0062% | $15.24 | $150,053 | -59.73% | ||
| 2024-02-12 | Sale | Principal Accounting Officer | 7,908 0.005% | $15.24 | $120,518 | -59.73% | ||
| 2023-12-14 | Sale | director | 9,926 0.0062% | $11.19 | $111,072 | -41.37% | ||
| 2023-11-20 | Sale | SVP, Chief Business Officer | 3,287 0.0022% | $9.69 | $31,851 | -16.44% |
Insider Historical Profitability
| Emany Sravan Kumar | SVP, COO and CFO | 309572 0.1934% | $4.45 | 2 | 2 | |
| Duane Jon R | director | 121028 0.0756% | $4.45 | 1 | 0 | |
| DENNER ALEXANDER J | 16390000 10.242% | $4.45 | 8 | 0 | +18.72% | |
| Ridgeback Capital Investments L.P. | 10 percent owner | 6842839 4.276% | $4.45 | 3 | 42 | <0.0001% |
| Hecht Peter M | Chief Executive Officer | 4696917 2.9351% | $4.45 | 1 | 16 | +9.03% |
Institutional Investor Ownership
| BlackRock | $210.41M | 15.2 | 24.16M | -7.01% | -$15.87M | 0.01 | |
| The Vanguard Group | $170.03M | 12.28 | 19.52M | +21.75% | +$30.38M | <0.01 | |
| Sarissa Capital Management LP | $142.76M | 10.31 | 16.39M | 0% | +$0 | 24.97 | |
| State Street | $121.22M | 8.76 | 13.92M | +20.68% | +$20.77M | 0.01 | |
| Pacer Advisors Inc | $62.77M | 4.53 | 7.21M | New | +$62.77M | 0.16 |